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Objective: Nearly, a third of obese individuals, termed metabolically benign obese, have a low burden of
adiposity-related cardiometabolic abnormalities, whereas a substantial proportion of normal-weight
individuals possess risk factors.
Methods: In cross-sectional analyses of 699 normal weight and 1,294 overweight/obese
postmenopausal women enrolled in a nested case-control stroke study ancillary to the Women’s Health
Initiative Observational Study, we compared levels of adiponectin, leptin, and resistin among
metabolically benign normal weight, at-risk normal weight, metabolically benign obese, and at-risk obese
women using components of the ATP III definition of the metabolic syndrome (metabolically benign: 1
of the four components; at-risk phenotype: 2 components or diabetes).
Results: Overall, 382/699 normal-weight women (54.6%) and 328/1,194 overweight/obese women
(27.5%) were metabolically benign. Among normal-weight women, at-risk women had higher leptin and
lower adiponectin levels compared to metabolically benign women; multivariate-adjusted odds ratios
were significant for having leptin (OR: 2.51; 95% CI: 1.28-5.01) and resistin (1.46; 1.03-2.07) in the top
tertile and adiponectin in the bottom tertile (2.64; 1.81-3.84). Compared to metabolically benign
overweight/obese women, at-risk obese women had higher odds of having leptin in the top tertile (1.62;
1.24-2.12) and adiponectin in the bottom tertile (2.78; 2.04-3.77).
Conclusions: Overall, metabolically benign overweight/obese women had an intermediate adipokine
profile (between at-risk obese and metabolically benign normal-weight women), whereas at-risk normal-
weight women had a less favorable profile compared to metabolically benign normal-weight women. As
adiponectin was the only adipokine independent of BMI, it may be most likely to have a role in the
etiological pathway of these phenotypes.
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Several studies have shown that a substantial proportion of obese
individuals (15-30%) (1-3), termed metabolically benign obese, pres-
ent with a low burden of adiposity-related cardiometabolic abnor-
malities, such as dyslipidemia, hypertension, and insulin resistance,
despite excess weight (4-6). Additionally, a substantial proportion of
normal-weight individuals possess several cardiometabolic abnor-
malities typically associated with obesity (‘‘at-risk’’ normal-weight
phenotype). Adipose tissue, a highly dynamic endocrine organ,
secretes numerous adipokines that are hypothesized to play a role in
the variation in cardiometabolic health observed among individuals
of similar body size. It is hypothesized that while healthy adipocytes
produce ‘‘optimal’’ levels of adipokines that support normal glucose
and lipid turnover and healthy endothelial function, adipose tissue
that has been significantly infiltrated by inflammatory cells produces
a pro-inflammatory milieu characterized by abnormally high levels
of leptin, resistin, tumor necrosis factor alpha (TNF-a), and interleu-
kin-6 (IL-6), as well as low levels of adiponectin. This milieu pro-
motes insulin resistance, endothelial dysfunction, increased oxidative
stress, and inflammation, which may lead to atherosclerosis (7-9).
We have previously shown that levels of inflammatory cytokines,
such as IL-6, TNF-a, plasminogen activator inhibitor-1 antigen
(PAI-1), and C-reactive protein (CRP), released in part by adipose
tissue but also by other tissues, are elevated in at-risk normal-weight
women compared to their metabolically benign normal-weight
counterparts and are lower in metabolically benign obese women
compared to their at-risk counterparts (10). Furthermore, a limited
literature shows that even among individuals with similar BMI, the
expression profile of adipokines is not uniform (11,12). Therefore,
the purpose of the current study was to examine levels of leptin,
resistin, and adiponectin among women of specific body size pheno-
types, participating in the Hormones and Biomarkers Predicting
Stroke (HaBPS) Study, an ancillary study to the Women’s Health
Initiative Observational Study (WHI-OS). We hypothesized that (1)
a more favorable adipokine profile, characterized by lower levels of
leptin and resistin and higher levels of adiponectin, may help
explain lower cardiometabolic risk among metabolically benign
obese women despite their excess weight, whereas (2) a less favor-
able adipokine profile may help explain elevated cardiometabolic
risk factors in at-risk lean women despite their normal weight.
Methods
Participants and study design
We used data from the HaBPS, a case-control study of incident is-
chemic stroke nested within the WHI-OS, aimed at examining the
relationships between various biomarkers and hormones measured in
the WHI-OS baseline blood specimens with the subsequent develop-
ment of ischemic stroke over follow-up. WHI-OS is an ongoing
multicenter prospective study, examining risk factors for the devel-
opment of health outcomes among US postmenopausal women
between 50 and 79 years of age at recruitment, who had no medical
conditions associated with an anticipated survival of <3 years. A
total of 93,676 women were recruited from October 1993 through
December 1998. The extensive inflammatory biomarker profile of
HaBPS study participants provided a unique opportunity to evaluate
the adipokine profile among various body size phenotype using
cross-sectional analyses of the baseline data, prior to the experience
of a stroke event. Therefore, although the HaBPS dataset consists of
matched case-control pairs, follow-up ischemic stroke case-control
status is considered as a covariate, rather than an outcome. Written
informed consent and appropriate institutional review board approval
were obtained by each participating WHI-OS site.
In the HaBPS study, 972 women with incident ischemic stroke diag-
nosed between study baseline and July 1, 2003 were matched to 972
controls on age at baseline (6 2 years), race-ethnicity, date of study
enrollment (6 3 months), and follow-up time (control follow-up
time  case follow-up time). Women with previous history of myo-
cardial infarction (MI) or stroke were excluded from the HaBPS
study. Exclusion criteria from the HaBPS dataset for the current
analyses were: missing values of body mass index (BMI; n ¼ 23),
as well as BMI in the underweight range (<18.5 kg/m2; n ¼ 22),
leaving data from 699 normal weight (18.5 BMI <25.0 kg/m2)
and 1194 overweight/obese (BMI  25 kg/m2) women for the
analyses.
Measurement of demographic, health behavior,
and physical factors
At the baseline visit, women completed self-administered question-
naires that included information on demographic and behavioral fac-
tors (education, income, smoking status, and physical activity), med-
ication use, medical history, and family history of cardiovascular
disease (CVD) and diabetes. The WHI physical activity question-
naire was self-administered at enrollment, where participants
reported the usual frequency, duration, and intensity of recreational
and household activities and exercise. Summary variables were then
created by combining frequency, duration, and MET-estimated in-
tensity in the following equation: [(frequency of activity per week 
minutes per session  MET for that activity)/(60 min/h)] to quantify
in ‘‘METhours’’, the total kilocalories expended per kilogram per
week. MET units are independent of body weight. The questionnaire
has been shown to have moderate to high test-retest reliability (13).
Additionally, each woman underwent a physical examination that
included anthropometric and blood pressure measurements, and col-
lection of fasting blood specimens (after 8 h or longer of fasting).
Height was measured with a wall-mounted stadiometer, and weight
was measured on a balance beam scale, with participants wearing
light clothing. BMI was calculated as weight in kilograms divided
by height in square meters. Waist circumference at the natural waist
or narrowest part of the torso was measured to the nearest 0.1 cm.
Blood pressure was measured using the right arm in a seated posi-
tion after a short rest and averaged across two readings.
Laboratory measurements
Baseline serum specimens (stored at 70C at the central reposi-
tory) were measured for levels of insulin, glucose, and lipids. Serum
insulin and glucose levels were measured by the Medical Research
Laboratories (Highland Heights, KY). Insulin resistance was esti-
mated using homeostasis model assessment (HOMA-IR) (14). Dia-
betes was defined as self-reported diabetes treatment or a fasting
glucose level 126 mg/dL. Total cholesterol, high-density lipopro-
tein cholesterol (HDL-C), and triglycerides (TG) were measured on
a Hitachi 911 analyzer with reagents from Roche Diagnostics
(Indianapolis, IN) and Genzyme Corporation (Cambridge, MA).
Low-density lipoprotein cholesterol (LDL-C) was calculated using
the Friedewald equation for women with TG 400 mg/dL (15).
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High-sensitivity CRP was measured by immunoturbidity initially,and
then by immunonephelometry. Plasma levels of adiponectin, leptin,
and resistin were measured by a multiplex assay (Human Adipokine
Panels A and B, Millipore, Billerica, MA); the inter-assay coeffi-
cients of variation were 11.3% for adiponectin, 5.3% for leptin, and
11.4% for resistin. Laboratory methods for all biomarkers measured
in the HaBPS study have been reported previously.16,17
Metabolically benign and at-risk phenotype
definitions
The primary analyses utilized components of the Adult Treatment
Panel-III (ATP-III) metabolic syndrome definition, excluding the
waist circumference component due to its collinearity with BMI.
Specifically, women were initially categorized as normal weight
(BMI < 25 kg/m2) or overweight/obese ( 25 kg/m2), and then fur-
ther categorized by metabolic status. Both normal-weight and over-
weight/obese women were classified as metabolically benign if they
had less than two of the following four ATP-III components: (1)
elevated blood pressure (systolic/diastolic BP130/85 mm Hg or
antihypertensive medication), (2) elevated TG (150 mg/dL or
lipid-lowering medication), (3) low HDL-C (<50 mg/dL), and (4)
elevated glucose (100 mg/dL or diabetes medication) (18). Nor-
mal-weight and overweight/obese women with two or more of the
four components were classified as at-risk. In addition, women were
classified as ‘‘at-risk’’ if they reported the use of anti-diabetic medi-
cation or had a fasting glucose of 126 mg/dL, regardless of the
number of other metabolic components. Sensitivity analyses exam-
ined the consistency of findings using three alternative definitions of
the metabolically benign phenotype: (1) modified ATP-III criteria
(1 of the four ATP-III criteria described above), and (2) the insulin
resistance-based (IR) definition among non-diabetic women only
(women were classified as metabolically benign if they had HOMA-
IR values less than the HOMA-IR values corresponding to the 25th
percentile of the distribution among non-diabetic obese participants
(HOMA-IR < 0.853) (19,20), and (3) using the ATP III definition
of metabolic syndrome, including waist circumference (with the
presence of 2 of the five components defining the metabolically
benign phenotype).
Statistical methods
Demographics, health history, median laboratory values, and median
adipokine levels were compared among metabolically benign nor-
mal-weight, at-risk normal-weight, metabolically benign overweight/
obese, and at-risk overweight/obese women, using the Kruskal-
Wallis non-parametric test for continuous data, and the chi-square
test for categorical data. Post-hoc between group comparisons were
completed using Bonferroni correction for both continuous and cate-
gorical data. Race-ethnicity was coded as ‘‘white’’ (Caucasian) and
‘‘others’’ (including black, Hispanic, Asian, American Indian, and
unspecified) since non-white race-ethnic groups were not present in
sufficient numbers to be analyzed separately.
Odds ratios (ORs) and 95% confidence intervals (CI) of being in the
top tertile of leptin and resistin and bottom tertile of adiponectin
associated with body size phenotypes were calculated using multi-
variate logistic regression modeling, adjusted for age, race-ethnicity,
stroke case status, smoking, physical activity, and hormone treat-
ment use (Model 1). To distinguish the effects of obesity, models
were further adjusted for BMI. Due to non-overlap of BMI between
the normal weight and overweight/obese groups, models were run
separately for the normal weight and overweight/obese groups, using
the benign phenotype as reference category. Tertile cutoffs were cal-
culated based on the entire sample of HaBPS participants (n ¼
1,993). A separate model was built for each adipokine.
In secondary analyses, ORs were re-calculated using the modified
ATP-III definition, the IR-based definition of the metabolically
benign phenotype, and the ATP-III definition to evaluate the consis-
tency of the results across several definitions. Additional sensitivity
analyses were restricted to controls only (women who did not
develop stroke), and (2) non-diabetic women. All statistical analyses
were performed using the SAS version 9.1 software (SAS Institute
Inc., Cary, NC), with the exception of box plots (Figure 1), which
were obtained using STATA version 11 (StataCorp LP., College




Baseline characteristics of normal-weight and overweight/obese
study participants are presented in Table 1. Overall, 382 out of 699
normal-weight women (54.6%) and 328 out of 1194 obese women
(27.5 %) were classified as metabolically benign. In both normal-
weight and overweight/obese groups, compared to metabolically
benign women, at-risk women were slightly older, less likely to be
white, reported lower levels of income, education, and physical
activity, had higher median values of BMI, waist circumference, and
CRP at baseline, and were more likely to have suffered a stroke
across follow-up.
Adipokine levels
Adipokine levels among metabolically benign normal weight, at-risk
normal weight, metabolically benign overweight/obese, and at-risk
overweight/obese women are presented in Figure 1. There was a
trend for increasing levels of leptin and resistin and decreasing lev-
els of adiponectin, going from metabolically benign and normal
weight to at-risk and obese. Specifically, at-risk normal-weight
women overall had significantly higher median levels of leptin (9.07
vs. 8.74 ng/mL) and resistin (2.5 vs. 2.4 ng/mL), but lower levels of
adiponectin (11.44 vs. 14.03 lg/mL) when compared to their meta-
bolically benign normal weight counterparts (Figure 1). Metabol-
ically benign overweight/obese women appeared to have intermedi-
ate levels of leptin and adiponectin, evidenced by higher levels of
leptin and resistin compared to the metabolically benign normal
weight group, but lower levels compared to their at-risk obese coun-
terparts (Figure 1). Median adiponectin levels were significantly
higher in the metabolically benign overweight/obese group com-
pared to the at-risk group, but the levels were not significantly
different from both the normal-weight phenotypes.
Multivariable-adjusted associations of tertiles of
adipokines with body size phenotypes
After multivariable adjustment, using the metabolically benign nor-
mal-weight phenotype as the reference category, the odd ratios of
possessing leptin and resistin in the top tertile, and adiponectin in
the bottom tertile, associated with being in the at-risk normal
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weight, metabolically benign overweight/obese, and at-risk over-
weight/obese phenotypes, are presented in Table 2. At-risk normal-
weight women had 2.5 times greater odds of having leptin levels
in the top tertile and 2.6 times greater odds of having adiponectin
in the bottom tertile, compared to their metabolically benign normal
weight counterparts (Table 2). The association was not statistically
significant for resistin.
Compared to metabolically benign normal-weight women, both met-
abolically benign and at-risk overweight/obese women had signifi-
cantly greater odds of having leptin and resistin in the top tertile.
Unlike leptin and resistin, the odds of being in the lowest tertile of
adiponectin were different between the benign and at-risk categories
of overweight/obese women, where metabolically benign women did
not show significantly greater odds of being in the lowest tertile of
adiponectin, metabolically at-risk overweight/obese women had
approximately four times higher odds.
Comparisons were then limited to within body size groups to allow
for adjustment of BMI. After further adjustment for BMI, the higher
odds of having leptin in the top tertile among metabolically benign
versus at-risk women noted above were attenuated, whereas the
higher odds of having resistin in the top tertile and adiponectin in
the bottom tertile remained significant (Table 3; Model 2).
Comparing differences in adipokine levels in the overweight/obese
women using the metabolically benign overweight/obese phenotype
as reference, at-risk overweight/obese women had 1.6 times signif-
icantly greater odds of having leptin in the top tertile and 2.8
times greater odds of having adiponectin in the bottom tertile
(Table 4; Model 1). After adjusting for BMI, the odds of having lep-
tin in the top tertile were attenuated, but the association remained
significant for adiponectin (Table 4; Model 2). The association with
top tertile of resistin was not statistically significant.
Sensitivity analyses
The odds ratios were similar, but results did not always reach statis-
tical significance when the modified ATP-III definition was used
(defining metabolically benign as 1 metabolic component of the
ATP III criteria), when the metabolically benign phenotype was
defined solely by levels of insulin resistance (HOMA-IR<25th per-
centile) (excluding women with self- reported diabetes treatment or
fasting glucose 126 mg/dL), or when the ATP III criteria including
waist circumference were used (see supplementary tables). Addi-
tional sensitivity analyses restricted to controls only (excluding
women who went on from these baseline data to suffer a stroke
across follow-up), and non-diabetic women also produced similar
findings (data not shown).
Discussion
Although a growing body of scientific literature recognizes the exis-
tence of metabolically benign overweight/obese and at-risk normal
weight phenotypes, the mechanisms underlying the variation in car-
diometabolic health even in individuals of similar levels of adiposity
remain unclear (1-3,6). In our study, at-risk normal weight post-
menopausal women presented with a less favorable adipokine profile
compared to their metabolically benign normal-weight counterparts,
FIGURE 1 Box plots representing median levels of leptin, resistin, and adiponectin by body size phenotypes.
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characterized by higher levels of leptin and resistin, and lower levels
of adiponectin. Metabolically benign overweight/obese women had
an intermediate adipokine profile, with higher levels of leptin and
resistin compared to normal-weight women, but lower levels of lep-
tin and resistin and higher levels of adiponectin compared to their
at-risk overweight/obese peers. After adjusting for BMI, the
TABLE 1 Baseline characteristics among normal weight (NW) and overweight/obese women
Metabolically
benign normal
weight (n ¼ 382)
At-risk normal
weight (n ¼ 317)
Metabolically benign
overweight/
obese (n ¼ 866)
At-risk
overweight/
obese (n ¼ 328) P
Age (years) 70.0 (8.0) 71.0 (8.0)§,# 68.0 (8.0)† 69.0 (9.0) <0.001
Race-ethnicity, n (%) <0.001
White 355 (93) 272 (86)§ 276 (84)† 721 (83)
Others 27 (7) 45 (14)§ 52 (16)† 145 (17)
Smoking, n (%) 0.185
Never 201 (53) 151 (48) 178 (55) 470 (55)
Former 149 (40) 137 (43) 130 (40) 344 (40)
Current 26 (7) 27 (9) 15 (5) 45 (5)
Education, %  high school 369 (97) 293 (93)§ 315 (96)‡ 788 (92) <0.001
Income, n (%)
<$35,000 137 (39) 147 (49)§ 153 (51)† 452 (57)
$35,000-$49,000 66 (19) 69 (23)§ 55 (18)† 149 (19)
 $50,000 146 (42) 81 (27)§ 95 (31)† 199 (25)
Hormone use, n (%) 0.002
Never 143 (37) 122 (38) # 140 (43) 423 (49)
Past 75 (20) 57 (18) # 54 (16) 145 (17)
Current 164 (43) 138 (44) # 134 (41) 298 (34)
Systolic blood pressure, mm Hg 121.0 (22.0) 136.0 (25.0)§ 124.0 (23.0)‡ 139.0 (22.0) <0.001
Diastolic blood pressure, mm Hg 71.0 (13.0) 74.0 (12.0)§,# 74.0 (12.0)†,‡ 77.0 (14.0) <0.001
Total cholesterol, mg/dL 221.0 (44.0) 235.0 (51.0)§ 230.0 (47.0)† 234.0 (51.0) <0.001
HDL cholesterol, mg/dL 68.0 (21.0) 55.0 (20.0)§,# 62.0 (18.0)†,‡ 49.0 (17.0) <0.001
LDL cholesterol, mg/dL 126.6 (40.8) 138.0 (46.2)§ 141.7 (45.3)† 143.6 (51.2) <0.001
Triglycerides, mg/dL 110.0 (49.0) 179.0 (86.0)§ 116.0 (46.0)‡ 184.0 (100.0) <0.001
Glucose, mg/dL 91.0 (8.0) 100.0 (16.0)§,# 93.0 (9.0)†,‡ 103.0 (23.0) <0.001
C-reactive protein, mg/mL 1.5 (2.6) 2.7 (3.9)§,# 2.7 (4.2)†,‡ 4.2 (5.6) <0.001
Elevated blood pressure, % 151 (40) 252 (80)§ 136 (42)‡ 733 (85) <0.001
Low HDL cholesterol, n (%) 28 (7) 151 (48)§,# 19 (6)‡ 515 (60) <0.001
Elevated triglycerides, n (%) 53 (14) 227 (72)§ 48 (14)‡ 640 (74) <0.001
Elevated glucose, n (%) 29 (8) 172 (54)§,# 33 (10)‡ 546 (63) <0.001
Insulin, uU/mL 3.7 (2.3) 5.6 (3.6)§,# 5.8 (4.2)†,‡ 9.6 (7.9) <0.001
HOMA-IR 0.8 (0.5) 1.3 (1.0)§,# 1.2 (0.9)†,‡ 2.3 (2.3) <0.001
Diabetes, n (%) 0 44 (14)§,# 0‡ 191 (22) <0.001
Aspirin use, n (%) 125 (33) 120 (38) 119 (36) 360 (42) 0.023
BMI (kg/m2) 22.4 (2.6) 23.2 (2.3)§,# 27.7 (4.3)†,‡ 29.5 (5.9) <0.001
Waist circumference (cm) 73.5 (8.9) 77.5 (9.0)§,# 87.3 (14.4)†,‡ 92.0 (14.0) <0.001
Physical activity, METs per week 15.3 (19.4) 11.4 (16.4)§,# 8.8 (16.3)† 7.5 (15.0) <0.001
Developed stroke during WHI follow-up, n (%) 151 (40) 166 (52)§ 132 (40)‡ 495 (57) <0.001
All continuous data presented as median (IQR); all categorical data presented as number (%).
The Kruskal-Wallis test used to examine differences between groups for continuous data. The Bonferroni test used for post-hoc analysis.
The chi-square test used to examine differences between groups for categorical data. The Bonferroni test used for post-hoc analysis.
†P value <0.05 for metabolically benign obese versus metabolically benign normal weight.
‡P value <0.05 for metabolically benign obese versus at-risk obese.
§P value <0.05 for at-risk normal weight versus metabolically benign normal weight.
#P value <0.05 for at-risk normal weight versus at-risk obese.The metabolically benign phenotype was defined as 1 of elevated blood pressure (130/85 mm Hg or
medication), elevated triglycerides (150 mg/dL), elevated fasting glucose (100 mg/dL or medication), low HDL-C (<50 mg/dL for women or medication).
The metabolically at-risk phenotype was defined as  2 of elevated blood pressure (130/85 mm Hg or medication), elevated triglycerides (150 mg/dL), elevated fasting
glucose (100 mg/dL or medication), and low HDL-C (<50 mg/dL for women or medication), OR if diabetic (self-report of diabetes treatment or fasting blood glucose 
126 mg/dL).
Obesity Adipokines in Metabolically Benign and At-Risk Women Khan et al.
790 Obesity | VOLUME 22 | NUMBER 3 | MARCH 2014 www.obesityjournal.org
differences between both the normal weight and obese groups were
attenuated for leptin but remained for adiponectin. The odds of hav-
ing higher levels of resistin remained in the normal-weight groups
but not in the overweight/obese groups after adjustment for BMI.
Among individuals with similar BMI levels, adipokine expression is
variable (12,21). Few studies have examined inflammatory marker
levels in metabolically benign obese individuals, and these have pro-
vided contradictory results, partially owing to the fact that some
studies have compared metabolically benign obese individuals to at-
risk obese individuals, whereas other studies have compared them to
healthy normal-weight individuals (21-25). In comparing all four
groups, Aguilar et al. found higher levels of adiponectin in the meta-
bolically healthy group compared to the at-risk group at each stra-
tum of BMI (21). Similar to our results, Labruna et al. did not find
difference in leptin levels between metabolically benign and at-risk
obese subjects (26). The role of resistin in worsening of cardiometa-
bolic health is more discrepant than that of adiponectin and appears
to be mainly due to inflammatory induction of endothelial dysfunc-
tion (27,28). In our study, resistin was associated with metabolic
health in the normal-weight group, even after adjustment for BMI
but was not associated with metabolic health in the overweight/
obese groups once BMI was accounted for. This difference in resis-
tin results after BMI adjustment between normal-weight and over-
weight/obese groups may be a statistical product, resulting from the
narrower BMI range in the normal-weight group.
Adipokine profile comparisons between metabolically benign obese
and healthy normal-weight individuals are less discrepant. A cross-
sectional study of 716 men and women found that metabolically be-
nign obese individuals (defined as having HDL 40 mg/dL and ab-
sence of type 2 diabetes or hypertension) had ‘‘higher than
TABLE 2 Adjusted odds ratios (95% confidence intervals) of having leptin and resistin levels in the top tertile, and adiponectin
levels in the bottom tertile, associated with body size phenotypes
Top tertile of leptin
(21.0-138.6 ng/mL)




OR 95% CI P OR 95% CI P OR 95% CI P
MBNW (n 5 372) 1.00 (reference) 1.00 (reference) 1.00 (reference)
ARNW (n 5 310) 2.53 1.28-5.01 0.008 1.39 0.98-1.95 0.064 2.64 1.81-3.84 <0.001
MBO (n 5 319) 16.84 9.24-30.68 <0.001 1.55 1.11-2.18 0.011 1.46 0.98-2.16 0.062
ARO (n 5 844) 27.03 15.22-48.00 <0.001 1.78 1.34-2.38 <0.001 4.08 2.95-5.65 <0.001
Model 1 ¼ adjusted for age, race, stroke case status, smoking, physical activity, and hormone therapy use
ARNW, at-risk normal weight; ARO, at-risk overweight/obese; MBNW, metabolically benign normal weight; MBO, metabolically benign overweight/obese. The metabolically
benign phenotype was defined as 1 of elevated blood pressure (130/85 mm Hg or medication), elevated triglycerides (150 mg/dL), elevated fasting glucose (100
mg/dL or medication), and low HDL-C (<50 mg/dL for women or medication).
The metabolically at-risk phenotype was defined as  2 of elevated blood pressure (130/85 mmHg or medication), elevated triglycerides (150 mg/dL), elevated fasting
glucose (100 mg/dL or medication), and low HDL-C (<50 mg/dL for women or medication). OR If diabetic (self-report of diabetes, fasting blood glucose  126 mg/dL
or on antidiabetic medication).
TABLE 3 Adjusted odds ratios (95% confidence intervals) of having leptin and resistin levels in the top tertile, and adiponectin
levels in the bottom tertile, associated with body size phenotypes
Top tertile of leptin
(21.0-138.6 ng/mL)
Top tertile of resistin
(14.2-182.6 ng/mL)
Bottom tertile of adiponectin
(0.0-21.8 lg/mL)
OR 95% CI P OR 95% CI P OR 95% CI P
Model 1
MBNW (n ¼ 372) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
ARNW (n ¼ 310) 2.51 1.25-5.07 0.014 1.46 1.03-2.07 0.036 2.87 1.95-4.24 <0.001
Model 2
MBNW 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
ARNW 1.96 0.95-4.04 0.067 1.50 1.05-2.15 0.027 2.53 1.70-3.76 <0.001
Model 1 ¼ adjusted for age, race, stroke case status, smoking, physical activity, and hormone therapy use
Model 2 ¼ Model 1 þ BMI
ARNW, at-risk normal weight phenotype; MBNW, metabolically benign normal weight phenotype.
The metabolically benign phenotype was defined as 1 of elevated blood pressure (130/85 mm Hg or medication), elevated triglycerides (150 mg/dL), elevated fasting
glucose (100 mg/dL or medication), low HDL-C (<50 mg/dL for women or medication).
The metabolically at-risk phenotype was defined as  2 of elevated blood pressure (130/85 mm Hg or medication), elevated triglycerides (150 mg/dL), elevated fasting
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expected’’ concentrations of adiponectin, in the same range as that
observed in lean subjects (21). (25) These results are consistent with
our current results also finding similar adiponectin levels in meta-
bolically benign overweight/obese compared to healthy normal-
weight women. Our recent study of inflammatory marker levels
(CRP, IL-6, TNF-a, PAI-1, WBC) among participants of the HaBPS
cohort suggested an intermediate pro-inflammatory burden among
metabolically benign obese women compared to healthy normal-
weight and at-risk overweight/obese women (10). Moreover, several
studies, including our own, suggest that the cardiometabolic health,
subclinical atherosclerosis, and clinical CVD burden of benign obese
individuals seems to be slightly worse than that of their ‘‘healthy’’
lean counterparts (metabolically benign normal-weight individuals)
(29-31). Our present data add to these findings showing an interme-
diate expression of adipokines in metabolically benign obese
women, with higher levels of pro-inflammatory leptin and resistin
but similar levels of anti-inflammatory adiponectin compared to
metabolically benign normal-weight women, and lower levels of lep-
tin and resistin and higher levels of adiponectin compared to at-risk
obese women. These findings raise the possibility that this differen-
tial expression of adipokines may contribute to the intermediate car-
diometabolic health and CVD risk of the metabolically benign obese
subgroup.
The at-risk normal-weight phenotype (also referred to as ‘‘metabol-
ically obese normal weight’’) is another unique subgroup that has
been recently gaining scientific interest. Despite having BMI in the
normal range, at-risk normal-weight individuals present with obe-
sity-related phenotypic characteristics, such as dyslipidemia, insulin
resistance, and hypertension. Several published studies suggest that
the prevalence of this phenotype ranges between 5% and 18%,
depending on the criteria used to define this subgroup (32,33).
Although the literature is limited, longitudinal studies, including our
own, have reported that these at-risk normal-weight individuals are
at higher risk for developing type 2 diabetes and CVD when com-
pared to their metabolically benign normal-weight counterparts and
metabolically benign obese individuals (19,34). Furthermore, our
prior examination of the HaBPS cohort demonstrated a pro-inflam-
matory state in at-risk normal-weight women, with higher levels of
multiple inflammatory markers, such as TNF-a, IL-6, CRP, white
blood cells, and e-selectin, compared to healthy normal-weight
women (10). The current results of higher levels of leptin and resis-
tin and lower levels of the anti-inflammatory adipokine adiponectin
are further evidence of a heightened inflammatory state despite nor-
mal BMI values and low waist circumferences.
In the current study, leptin levels were more strongly associated
with obesity status than metabolic status since leptin levels were sig-
nificantly higher in obese women than normal-weight women
regardless of their metabolic state, and differences between at-risk
and benign women were attenuated after adjusting for BMI in both
the normal weight and overweight/obese groups, whereas adiponec-
tin levels seemed to be much more strongly influenced by the meta-
bolic state than by BMI. High leptin levels have been associated
with both insulin secretion and inflammation (35) by up-regulating
the expression of pro-inflammatory and pro-angiogenic factors (36).
In contrast, adiponectin, the most abundant adipose tissue-specific
adipokine in circulation, (37) improves peripheral insulin sensitivity,
improves fatty acid oxidation in liver and muscle, (35) and induces
the production of anti-inflammatory cytokines (37).
Early evidence suggests that adipocyte hypertrophy is associated
with pro-inflammatory changes in the adipokine profile (38). And,
recent data suggest that omental (visceral), but not subcutaneous adi-
pokine secretion, is associated with metabolic health (39), independ-
ent of body composition (40). Therefore, it is possible that differen-
ces in adipocyte size and adipose tissue distribution, despite similar
overall body size, may partially determine differences in adipokine
levels between benign and at-risk phenotypes, independent of BMI.
Both at-risk normal-weight and obese women had larger waist cir-
cumference than their metabolically benign counterparts. However,
adjustment for waist circumference in our sensitivity analyses,
though not a perfect proxy for abdominal adipose tissue, had the
minimal effect on the estimates, suggesting that adjustment for
TABLE 4 Adjusted odds ratios (95% confidence intervals) of having leptin and resistin levels in the top tertile, and adiponectin
levels in the bottom tertile, associated with body size phenotypes
Top tertile of leptin
(21.0-138.6 ng/mL)
Top tertile of resistin
(14.2-182.6 ng/mL)
Bottom tertile of adiponectin
(0.0-21.8 lg/mL)
OR 95% CI P OR 95% CI P OR 95% CI P
Model 1
MBO (n ¼ 319) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
ARO (n ¼ 844) 1.62 1.24-2.12 <0.001 1.12 0.85-1.48 0.429 2.78 2.04-3.77 <0.001
Model 2
MBO 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
ARO 1.22 0.91-1.62 0.180 1.02 0.77-1.36 0.876 2.60 1.91-3.55 <0.001
Model 1 ¼ adjusted for age, race, stroke case status, smoking, physical activity, and hormone therapy use
Model 2 ¼ Model 1 þ BMI
ARO, at-risk overweight/obese phenotype; MBO, metabolically benign overweight/obese phenotype
The metabolically benign phenotype was defined as 1 of elevated blood pressure (130/85 mm Hg or medication), elevated triglycerides (150 mg/dL), elevated fasting
glucose (100 mg/dL or medication), low HDL-C (<50 mg/dL for women or medication).
The metabolically at-risk phenotype was defined as  2 of elevated blood pressure (130/85 mm Hg or medication), elevated triglycerides (150 mg/dL), elevated fasting
glucose (100 mg/dL or medication), low HDL-C (<50 mg/dL for women or medication). OR if diabetic (fasting blood glucose  126 mg/dL, or self-report of diabetes or
on antidiabetic medication).
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visceral adipose tissue may not completely eliminate these differen-
ces either. Further research in these areas is warranted.
The limitations of our study should be noted. Our findings are only
generalizable to postmenopausal women primarily of Caucasian
race-ethnicity, who evidence a lower prevalence of overweight and
obesity than the general population. Additionally, whether the adipo-
kine variation in women of similar body size demonstrated here is a
precursor to variation in cardiometabolic health, or rather, results
from the cardiometabolic risk factors, themselves, or both, cannot be
addressed by the cross-sectional design of our analyses. In addition,
we recognize that obesity is a multifactorial disorder, and we were
unable to evaluate several other components, such as diet, alcohol
intake, genetic factors, or adipose tissue distribution.
Despite these limitations, our study has a number of strengths. The
nesting of this study within the WHI-OS allowed us to assess a
much larger number of overweight/obese women who had an exten-
sive assessment of their adipokine profile. In addition, we were not
only able to evaluate adipokine levels among the overweight/obese
population, but also to make comparisons to both metabolically be-
nign and at-risk normal-weight women.
In summary, our study supports the concept that the adipokine profile
within normal-weight individuals as well as within overweight/obese
individuals is not uniform and may play a role in the cardiometabolic
health of metabolically benign and at-risk phenotypes. Metabolically
benign overweight/obese women presented with an intermediate adi-
pokine profile, while at-risk normal-weight women had a less favor-
able adipokine milieu compared to their metabolically benign counter-
parts. The etiology of both of these unique phenotypes appears to be
multifactorial, and whereas adipokines are likely not the only determi-
nants, they may be a component of the etiological pathway. More ba-
sic science and epidemiologic research is needed to understand the
complex cross-talk between inflammatory and metabolic processes
among these two phenotypes.O
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